16 September 2026 editorial review · Trial
PRISE-hATG: SAB-142 in recent-onset and established type 1 diabetes: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the trial evidence page →Baseline trial evidence review: M–S
Outcome: Corrected random vsstimulated screeningCpeptide and passedestimatedstart; removed absolute onceever rabbitATG claim. Corrected direct item relationships; shared class or background is insufficient.
Registry: NCT07670650. Endpoint reviewed: Area under the concentration-time curve (AUC) of C-peptide after a 2 hour mixed meal tolerance test (MMTT) (Dose administration to 12 Months). Eligibility reviewed: Age 5 Years to 40 Years; diagnosis/stage, prior therapy and key biomarker criteria compared with site summary. Full exclusions remain in the registry. Literature access limit: No usable primary abstract was independently recovered for this record in this pass. Current registry protocol was the main source; detailed sponsor or conference data remain dependent on the cited source and were not fully reverified.